KCT0004408进行中（未招募）未知
Randomized, Double-blind, and Placebo-controlled a Clinical Study for Growing of Stature via the Analysis of Effect of Ferment Oyster Extract
Pusan National University Korean Medicine Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 6(Year) 至 11(Year)（—）
- 性别
- All
入选标准
- •(1) Children up to the 25th percentile by age and gender for the 2017 standard growth chart percentile by idiopathic
- •(2) After fully hearing and understanding the details of this clinical trial, you agree to participate voluntarily and agree in writing to abide by the instructions
排除标准
- •(1) Those who have a growth delay due to endocrine diseases (growth hormone deficiency, hypothyroidism, type 1 diabetes, etc.)
- •(2) Those who have precocious puberty (female Tanner stage II under 8 years old, Testicular size Tanner stage II under 9 years old)
- •(3) A person who is being treated for the manifestation of a serious infectious disease or a tumor.
- •(4) Those who received growth hormone within 4 weeks prior to visit 1
- •(5) Those who have taken medicines and health foods aimed at improving kidney growth within two weeks prior to visit 1
- •(6) diabetic patients with uncontrolled blood glucose (when fasting glucose is above 126 mg / dL or when typical symptoms of diabetes (polyuria, then unexplained weight loss and any blood sugar over 200 mg / dL))
- •(7) Those whose TSH, T3, and FT4 test values ??deviate from the normal values ??of the research institute
- •(8) Those who have abnormal renal function that is more than twice the normal upper limit of each Creatinine organ
- •(9) A person with abnormal liver function that is more than twice the normal upper limit of each AST (GOT) or ALT (GPT) organ.
- •(10) Those who are currently being treated for severe heart disease such as congenital heart disease
- •(11) A person who plans to participate in other tests during this human application test.
- •(12) those who are taking methylphenidate drugs with ADHD
- •(13) Allergic to shellfish
- •(14) The person in charge judges that it is not suitable for other tests.
研究者
相似试验
进行中（未招募）
1 期
Clinical investigation of the safety and anti-diabetic efficacy of the Rauvolfia-Citrus decoctioon-insulin dependent diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10012637Term: Diabetes with peripheral circulatory disordersSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: LLTClassification code 10045248Term: Type II diabetes mellitus with other specified manifestationsSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10045252Term: Type II diabetes mellitus without mention of complicationSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10012640Term: Diabetes with unspecified complicationsSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000436-25-DKFrederiksberg University Hospital250
进行中（未招募）
1 期
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney diseaseMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disorderschronic kidney diseaseEUCTR2021-001434-19-PLBoehringer Ingelheim RCV GmbH & Co KG552
进行中（未招募）
1 期
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney diseasechronic kidney diseaseEUCTR2021-001434-19-GRBoehringer Ingelheim B.V552
进行中（未招募）
1 期
A study to test whether two different doses of BI 685509 help people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-001285-38-FRBoehringer-Ingelheim France150
尚未招募
2 期
A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver) who had bleeding in the esophagus or fluid accumulation in the bellyJPRN-jRCT2031230564Taguchi Aya40